(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMPOSIÇÃO PARA O TRATAMENTO DE DISTROFIA MUSCULAR DE DUCHENNE

ArquivadaInvention PatentPCT · GB2017050884

Application data

Number

112018070076

Type

Invention Patent

Filing

03/29/2017

Publication

05/21/2019

PCT

GB2017050884

Progress at the INPI

  1. Filing03/29/17
  2. Publication05/21/19
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 03/29/2017 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 09/21/2021. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

SUMMIT (OXFORD) LIMITED

GB

Inventors

G. H. (pessoa física)

GB

Technical data

IPC Classification

Priority claims

GB

1605383.7 · 03/30/2016

GB

1612920.7 · 07/26/2016

Abstract

A presente invenção se refere a dispersões sólidas amorfas que compreendem o composto 5-(etilsulfonil)-2-(naftalen-2-il)benzo[d]oxazol (ezutromid) e um polímero. As ASDs encontram aplicação no tratamento ou profilaxia de dis-trofia muscular de Duchenne e distrofia muscular de Becker.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Adição na publicação

#15.35

09/21/2021

RPI 2646

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

09/15/2020

RPI 2593

Arquivamento - Art. 33 da LPI

#11.1

06/30/2020

RPI 2582

Notificação de entrada na fase nacional - PCT

#1.3

05/21/2019

RPI 2524

Exigências diversas

#1.5

Apresente o complemento do texto, em português, do relatório descritivo e, se houver, dos desenhos, conforme determina a Resolução INPI PR nº 77/2013 de 18/03/2013, Art. 5º e 7º.

02/12/2019

RPI 2510

Alteração de dados cadastrais

#1.1

10/16/2018

RPI 2493

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.